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Mature peripheral T cell lymphomas (PTCLs) are a heterogeneous group of disorders collectively comprising 10-15% of non-Hodgkin's lymphomas 1 . These cancers typically behave aggressively 2, 3 . Outcomes are worse than those for equivalent B cell cancers and include an overall estimated 5-year survival of only 32% (ref. 3) . Furthermore, although treatment approaches for B cell cancers include targeted immunotherapies, such as therapeutic monoclonal antibodies 4 , bispecific T cell engagers 5 and, more recently, CAR T cell therapy 6, 7 , no such approaches are available for treatment of T cell cancers.
Immunotherapies used for B cell malignancies target pan-B cell antigens because there are no antigens that discriminate normal from malignant B cells. The consequent depletion of the normal B cell compartment is surprisingly well tolerated and is considered an acceptable side-effect 6, 7 . The situation is different with T cells: again, there are no antigens that discriminate normal from malignant T cells 3, 8 , but the T cell aplasia consequent to targeting a pan-T cell antigen would lead to profound and unacceptable immunosuppression 9 . Here we describe a targeting approach for treating mature T cell cancers that relies on recognition of a pan-T cell antigen but avoids severe immunosuppression.
The αβ TCR is a pan-T cell antigen. Apart from its expression on normal T cells, it is a highly promising target for treatment of PTCL: it is expressed by >95% of cases of PTCL, not otherwise specified (PTCL-NOS) 8 and almost all angioimmunoblastic T cell lymphomas (AITLs) 8 as well as by 30% of T cell acute lymphoblastic leukemias (T-ALLs) 10 . High and homogenous cell-surface expression of the αβ TCR is commonly seen on lymphoma cells 11 . In addition, evidence exists that a proportion of PTCL cases may depend on TCR-associated signaling for lymphomagenesis and survival 12 .
TCR α and β chains comprise N-terminal variable and C-terminal constant regions 13 (Fig. 1a) . TCR diversity is generated by somatic recombination, which occurs when each TCR chain selects a variable (V), diversity (D), joining (J) and constant (C) region 13 . Importantly, all cells in a clonal T cell population express the same unique TCR. However, approaches targeting the TCR variable region unique to a malignant clone are impracticable, as a bespoke therapeutic would be required for each patient.
An often forgotten feature of TCR β-chain recombination is that there are two genes associated with the β-chain constant region: TRBC1 and TRBC2. Each TCR (and therefore each T cell) irreversibly selects a TCR β-chain constant region encoded by either TRBC1 or TRBC2 for expression in a mutually exclusive manner 14, 15 ( Fig. 1b) . Hence, a population of normal T cells will comprise a mixture of individual cells, some expressing TRBC1 and others expressing TRBC2, whereas the entire population of T cell cancer will exclusively express either TRBC1 or TRBC2. We propose targeting TRBC1 in the case of a TRBC1 + T cell malignancy or TRBC2 in the case of a TRBC2 + malignancy. This will eradicate all cells of the malignant clone but will leave a substantial proportion of the T cell compartment intact.
In this work, we demonstrate that it is possible to distinguish between TCRs with TRBC1 and TRBC2 (TRBC1-and TRBC2-TCRs) with an antibody despite their almost identical amino acid sequences (Fig. 1c) . We show that peripheral blood T cells in healthy subjects comprise a mixture of approximately 35% TRBC1 + and 65% TRBC2 + cells and that complete depletion of either the TRBC1 + or TRBC2 + T cell compartment still results in the maintenance of a considerable antiviral repertoire. We confirm TRBC monoclonality in many types of T cell malignancies by both flow cytometry and immunohistochemistry (IHC) . Finally, we demonstrate the efficacy of a CAR T cell therapy with TRBC1 specificity to prove the validity of our targeting concept.
RESULTS

JOVI-1 monoclonal antibody is specific for TRBC1-expressing cells
To find a TRBC-specific binder, we screened anti-TCR monoclonal antibodies that were known to bind a proportion of T cells in peripheral blood. In order to screen for TRBC1 versus TRBC2 specificity, we cloned the sequence encoding the α and β chains of the wellcharacterized HA-1 TCR 16 either in its wild-type format encoding TRBC2 or with mutations mapping to its constant domain to yield TRBC1 instead. We stably expressed either TCR on the surface of the Jurkat T cell line in which the TCR α-and β-chain loci are knocked out (JKO). Analysis by flow cytometry demonstrated that, although both TRBC1-JKO and TRBC2-JKO lines expressed surface TCR-CD3 complex, the JOVI-1 monoclonal antibody 17 recognized only TRBC1-JKO cells and not TRBC2-JKO cells (Fig. 1d) , confirming the TRBC1 specificity of this antibody. In surface plasmon resonance analysis, JOVI-1 bound to the TRBC1-TCR with an affinity of K D = 0.42 nM and a half-life of ~30 min, in line with the parameters for other therapeutic antibodies 18 . In contrast, JOVI-1 binding to the TRBC2-TCR was >10,000-fold weaker, demonstrating the remarkable specificity of this reagent (Supplementary Fig. 1) .
TCR β-chain junctional regions segregate with constant domains: TCRs selecting TRBJ1-1 through TRBJ1-6 use TRBC1, and those selecting TRBJ2-1 through TRBJ2-7 use TRBC2 (ref. 13 ). Therefore, it is possible that JOVI-1 only maintains specificity for TRBC1 in the context of particular junctional regions. We cloned the sequences for several TCRs with varying antigen specificity, utilizing a range of variable and junctional regions, from publicly available sequences. When these sequences were transfected into HEK-293T cells along with a plasmid supplying the components of CD3, TCRs were expressed on the cell surface. JOVI-1 uniformly recognized TRBC1 + cells in spite of varying TRBJ1 regions and did not recognize cells expressing TRBC2-TCRs with varying TRBJ2 regions (Fig. 1e) . In addition, (f) JOVI-1 staining of engineered JKO cell lines stably expressing truncated TCRs lacking the variable region (∆TRBC1 or ∆TRBC2) or TCR constructs in which TRBC1 amino acids were individually introduced into TRBC2 at the sites at which the two proteins differ (gated on CD3 + cells). (g) 3D representation of the discriminating TRBC1 and TRBC2 epitopes on the surface of the TRBC domains. Asparagine and lysine residues are highlighted, and the exposed lysine residue in the TRBC1 epitope is indicated by a black arrow.
we cloned the sequence for a truncated TCR lacking α-and β-chain V(D)J domains and stably expressed it on the surface of JKO cells. CD3 staining confirmed cell-surface assembly of the truncated TCR, and staining with JOVI-1 was similar to that seen for the full-length TCR (Fig. 1f) . This offers further confirmation that specific junctional regions are not required for the JOVI-1 epitope.
We then sought to determine the residues of the TRBC domains responsible for the TRBC1 specificity of JOVI-1. Structural analysis suggested that Phe36 in TRBC1 (Tyr36 in TRBC2) is buried in secondary structure and Val113 (Glu113) is likely too close to the membrane to be accessible. However, Asn4 and Lys5 are exposed to the surface, and alteration of these residues to Lys4 and Asn5 in TRBC2 results in a substantial difference in both the shape and charge of the epitope relative to TRBC1. By introducing each mutation required to convert TRBC2 to TRBC1 individually and then stably expressing these constructs on the surface of JKO cells, we confirmed that residues 4 and 5 indeed constitute the discriminating portion of the JOVI-1 epitope (Fig. 1f,g ).
Normal ab T cell populations contain a mixture of TRBC1 + and TRBC1 − cells Using JOVI-1, we next sought to determine the proportion of T cells from healthy donors that were TRBC1 + versus TRBC2 + . Each donor had TCR + TRBC1 + and TCR + TRBC1 − cells in both their CD4 + and CD8 + T cell compartments; the median percentage of total T cells expressing TRBC1 was 35% (range, 25-47%; Fig. 2a,b) . We also confirmed that all CD4 + and CD8 + differentiation subsets contained both populations, with TRBC1:TRBC2 ratios similar to that observed for the total T cell population (Supplementary Fig. 2a,d ). In addition, we analyzed two cell types that express a semi-invariant restricted TCR repertoire: mucosal-associated invariant T cells (MAITs; Supplementary  Fig. 2b,d ) and invariant natural killer T cells (iNKTs; Supplementary  Fig. 2c,d) . We found that these populations also contained both TRBC1 + and TRBC1 − cells, albeit with a lower proportion of TRBC1 + cells than that seen in bulk T cell populations.
Although the polyclonal T cell population in normal donors contained both TRBC1 + and TRBC2 + cells, we reasoned that the T cell response to a particular virus might be skewed toward one of these subpopulations and that removal of one subset could therefore result in loss of cellular immunity. To determine whether this was the case, we generated oligoclonal Epstein-Barr virus (EBV)-specific cytotoxic T cell lines (CTLs) using cells from three healthy donors, as previously described 19 (Supplementary Fig. 3a) . These cells lysed autologous EBV-transformed cells (Supplementary Fig. 3b ). Staining revealed that >98% of the cells were CD8 + (data not shown) and they constituted a mixed population of TRBC1 + and TRBC1 − cells (median, 45% TRBC1 + ; Supplementary Fig. 3c ), demonstrating that the T cell response to EBV involves both subpopulations (Fig. 2c) . In addition, we identified T cells specific for cytomegalovirus (CMV) or adenovirus (AdV) through incubation of peripheral blood mononuclear cells (PBMCs) with pools of antigenic peptides. Virus-specific T cell populations, identified by interferon (IFN)-γ expression after peptide incubation (Supplementary Fig. 3d ), were found to contain both TRBC1 + and TRBC1 − cells (Fig. 2d) . Summary data from healthy donors revealed a median TRBC1 positivty of 45% (CMV specific) and 41% (AdV specific) among the virus-specific T cells (Fig. 2e) .
T cell-malignancy-derived cell lines and primary T cell cancers are clonally TRBC1 + or TRBC1 − Cell lines with cell-surface expression of TCR were stained with JOVI-1 and found to be either TRBC1 + (H9, Jurkat, MJ) or TRBC1 − (HDMar2, HPB-ALL, T-ALL1, HH). TRBC1 versus TRBC2 expression was confirmed at the transcript level through PCR amplification of the β-chain constant region from cDNA followed by Sanger sequencing (Fig. 3a) . These data confirm JOVI-1 as a marker of TRBC1 monoclonality in cell lines. Next, using multiparameter flow cytometry, we analyzed primary blood samples from several individuals with T cell large granular lymphocytic leukemia (T-LGLL), a TCR + lymphoproliferative disorder characterized by circulating cancer cells that express CD57 (ref. 20) . Whereas CD57 + malignant cells demonstrated markedly skewed TRBC1:TRBC2 ratios, normal CD4 + and CD8 + T cells displayed normal ratios for these populations (Fig. 3b) . Using intracellular staining, we replicated this finding in primary bone marrow samples of T-ALL (Fig. 3c) . Further, using fluorescence-activated cell sorting (FACS) or IHC on frozen tissue sections, we stained a number of primary samples of TCR + malignancies of multiple histologies and confirmed that TRBC1 staining could be used to determine whether cancer cells were clonally TRBC1 + or TRBC1 − (Fig. 3d,e) . Of 57 samples (38 analyzed by IHC, 19 analyzed by FACS), 39% were TRBC1 + and 61% were TRBC1 − ( Table 1) . Of note, TCR-CD3 complex expression assayed by FACS in primary malignancies was typically at a level similar to that in normal T cells from the same subject (median MFI (median fluorescence intensity) = 96% of normal T cell MFI), other than in adult T cell leukemia/lymphoma (ATLL), in which expression was typically weaker than in normal T cells (median MFI = 23% of normal T cell MFI; Fig. 3f ).
T cells transduced to express anti-TRBC1 CAR specifically target TRBC1 + and not TRBC2 + cells in vitro We cloned the sequence for a single-chain variable fragment based on the JOVI-1 epitope into a third-generation CAR format 21 as a proof of concept for therapies targeting TRBC. We retrovirally transduced T cells from healthy donors to stably express this construct and confirmed surface expression of CAR on up to 90% of cells (Fig. 4a) . We subsequently co-cultured nontransduced (NT) or (Fig. 4b,c) . In 4-h chromium-release cytotoxicity assays, NT effector cells did not display cytotoxicity, whereas anti-TRBC1 CAR T cells specifically killed TRBC1-JKO and not NT-JKO or TRBC2-JKO cells (Fig. 4d,e) .
In addition, we performed flow cytometric cytotoxicity assays using multiple αβ TCR + cell lines as targets and confirmed killing of cells expressing TRBC1-TCRs, but not TRBC2-TCRs, by anti-TRBC1 CAR T cells, whereas NT T cells did not lyse either (Fig. 4f) . Next, to simulate a physiological setting, we mixed TRBC1-JKO cells labeled with CD19 marker with TRBC2-JKO cells labeled with blue fluorescent protein (BFP) in a 1:1 ratio. This population was co-cultured with anti-TRBC1 CAR or NT T cells. Analysis 48 h later confirmed eradication of TRBC1 + cells with preservation of TRBC2 + cells by anti-TRBC1 CAR T cells, whereas no killing of either population was seen with NT effectors (Fig. 4g) .
We obtained primary malignant cells from multiple individuals with TRBC1 + T cell malignancies. We co-cultured subject-derived neoplastic cells with NT or anti-TRBC1 CAR T cells in a 1:1 ratio.
Using allogeneic T cells, we found specific killing of malignant cells in cases of T cell prolymphocytic leukemia (T-PLL) and PTCL-NOS with preservation of a substantial proportion of normal T cells (Fig. 4h) . Malignant cell killing was seen even in cases of ATLL (Fig. 4i,l) in which TCR-CD3 complex was partially downregulated from the cell surface (Fig. 3f) . In addition, we successfully transduced T cells from an individual with TRBC1 + malignancy (ATLL) despite a heavy burden of circulating ATLL cells (Fig. 4j) , resulting in the T cell product being 'purged' of contaminating ATLL cells (Fig. 4k) through the specific killing of autologous ATLL cells by anti-TRBC1 CAR T cells (Fig. 4l) .
Anti-TRBC1 CAR T cells selectively deplete normal TRBC1 + , but not TRBC2 + , cells Following transduction of healthy donor T cells with virus encoding anti-TRBC1 CAR, no TRBC1 + cells could be detected in either the transduced or NT fractions, indicating possible depletion of this population (Supplementary Fig. 4a ). However, we reasoned that absence of TRBC1 staining was likely due to epitope blocking by ligated anti-TRBC1 CAR. Therefore, we transduced cells to express anti-TRBC1 CAR and the CD34 marker 22 . This enabled sorting of cells into CAR + and CAR − fractions using CD34 MicroBead magnetic depletion. We Fig. 4b ). Further, we sorted healthy donor T cells into TRBC1 + and TRBC1 − populations using magnetic beads. We subsequently separately labeled each population with different fluorescent nuclear dyes, enabling later discrimination of the populations, and co-cultured them with autologous NT or anti-TRBC1 CAR T cells. Whereas TRBC2 + cells co-cultured with anti-TRBC1 CAR T cells were not depleted as compared to the NT condition, 80% of all TRBC1 + cells were gone at 7 d (Supplementary Fig. 4c ), indicating selective purging of this population. This was confirmed in a further assay in which TRBC1 + cells were mixed with TRBC2 + cells in a 1:2 ratio (the physiological condition) before 1:1 co-culture with NT or anti-TRBC1 CAR T cells. After 7 d of co-culture, virtually all of the TRBC1 + cells had been depleted from the culture, whereas TRBC2 + cells remained ( Supplementary  Fig. 4d) . Finally, to test a strategy to further mitigate potential transduction of contaminating TRBC1 + cancer cells, we predepleted TRBC1 + cells from healthy donor T cells to obtain a population of cells that was >99% TRBC1 − ( Supplementary Fig. 4e ) for which we achieved transduction with viruses encoding anti-TRBC1 CAR similar to that achieved for unsorted cells (Supplementary Fig. 4f ).
Anti-TRBC1 CAR T cells are specific and effective in mouse models of disseminated T cell malignancy NOD-SCID gamma (NSG) mice were intravenously injected with Jurkat T cells, which natively express TRBC1-TCR at a level similar to that in primary malignant and normal T cells (Fig. 3f) . Jurkat cells were modified to stably express firefly luciferase (FLuc) and the CD19 marker, and were stably engrafted in the bone marrow of all injected animals by day 6 (Fig. 5a,b) . Following engraftment, we treated mice with T cells expressing anti-TRBC1 CAR or an irrelevant control CAR. Mice treated with anti-TRBC1 CAR T cells had a dramatic reduction of Jurkat cell burden by bioluminescence imaging (BLI) at day 10 after injection ( Fig. 5b,c) , and this reduction was associated with a substantial survival benefit. In an additional experiment evaluating CAR persistence (Fig. 5e) , we observed Jurkat cell clearance and increased numbers of anti-TRBC1 CAR T cells versus control CAR T cells in peripheral blood at day 21 following T cell injection (Fig. 5f) . Bone marrow was collected at the time of death (survivors killed at day 42), and similar results were obtained (Fig. 5g) .
Next, we injected another cohort of mice with equal proportions of TRBC1-expressing Jurkat cells (TRBC1-Jurkat; also expressing human CD19 marker) and JKO cells engineered to express TRBC2-TCR and BFP marker. Jurkat cell engraftment in bone marrow was confirmed in all mice through BLI at day 6. Mice were then treated with NT or anti-TRBC1 CAR T cells. Flow cytometry of bone marrow confirmed the TRBC1 specificity of anti-TRBC1 CAR T cells in vivo: mice that received NT effectors had approximately equal proportions of TRBC1-Jurkat and TRBC2-JKO cells, whereas only TRBC2-JKO cells were seen in the recipients of anti-TRBC1 CAR T cells (Fig. 5e,f) .
Finally, in order to determine whether anti-TRBC1 CAR T cells would be able to deplete TRBC1-Jurkat cells in a physiological setting (i.e., in the presence of normal T cells), we engrafted NSG mice with Jurkat cells expressing CD19 and FLuc as before. After 7 d, mice were injected with human PBMCs (Supplementary Fig. 5a ). After an additional 7 d, human monocyte and T cell engraftment was confirmed by flow cytometry of peripheral blood (Supplementary Fig. 5b) , and progressive disease was demonstrated by BLI ( Supplementary  Fig. 5c ). Mice were then injected with anti-TRBC1 CAR T cells or control CAR T cells using cells prepared from the same donor as the initial PBMCs. BLI and flow cytometry of bone marrow at 5 d following treatment demonstrated Jurkat cell control in the recipients of anti-TRBC1 CAR T cells but progression in those receiving control CAR T cells (Supplementary Fig. 5c-e) . Flow cytometry analysis of bone marrow (Supplementary Fig. 5e ) and spleen ( Supplementary  Fig. 5f ) at day 6 following treatment demonstrated that similar numbers of non-CAR T cells were present in the recipients of anti-TRBC1 and control CAR T cells, confirming the persistence of normal T cells in the face of Jurkat cell depletion.
DISCUSSION
The presence of two functionally identical genes in the locus for the TCR β-chain constant region has been recognized for more than 30 years 14,15 but, to our knowledge, has not been exploited until now. We have demonstrated that it is possible to discriminate between TRBC1 and TRBC2 domains on normal and malignant T cells, despite their highly similar amino acid sequences. Indeed, JOVI-1 showed a >10,000-fold difference in binding affinity for the two, with specificity based on the identity of only two residues in the TRBC sequences. Consistent with previous findings, we have shown that approximately two-thirds of both normal T cells 23, 24 and cells from T cell malignancies 25 express TRBC2-TCR.
We believe that TRBC1 or TRBC2 targeting has considerable potential as an immunotherapy for T cell malignancies. The principle of using immunotherapy to target a rearranged clone-specific receptor is not new: Stevenson and colleagues 26, 27 pioneered the use of patient-specific anti-idiotype monoclonal antibodies against neoplastic lymphoma cells. However, this approach is impracticable because it requires a new binder to be generated for each patient. An analogous approach to ours, namely treating B cell cancers through specific targeting of antibody light chain, has also been proposed 28 .
Patients with B cell malignancies have greatly benefited from the advent of potent immunotherapies. Treatment of B cell malignancies with anti-CD19 CAR T cells has been one of the most important recent advances in the treatment of cancer: sustained remissions have been obtained in most patients with advanced and refractory B-ALL 6, 29 , as well as impressive though lesser responses in chronic lymphocytic leukemia 7, 30 and diffuse large B cell lymphoma 7 . Given the relatively similar presentation and nature of B and T cell malignancies, CAR T cells could potentially have similar value in treating T cell lymphomas. However, anti-CD19 CAR T cell efficacy is accompanied by loss of the normal B cell compartment 6, 7 . Although this is relatively well tolerated and the impact can be lessened by infusion of donor-derived pooled immunoglobulins, analogously targeting a pan-T cell antigen on a T cell malignancy (with concomitant permanent loss of normal T cells) would be prohibitively toxic, with no mitigating replacement therapies available.
Approaches using CARs against T cell targets such as the pan-T cell antigens CD5 (ref. 31) or CD4, which are present on a crucial subset of normal T cells 32 , have been proposed but may prove unacceptably immunosuppressive in clinical use. With our approach, a patient treated with anti-TRBC1 CAR T cells would retain approximately twothirds of their normal T cells, with polyclonal antiviral immunity likely preserved. In addition, the potential for 'on-target, off-tumor' toxicity affecting other tissues would be negligible, given the restriction of TCR expression to mature T and NKT cells. However, with any approach targeting T cells rather than B cells, increased cytokine-mediated toxicity could occur owing to lysis of normal tissue-resident T cells and subsequent mediator release. Another potential consequence of depletion of part of the regulatory T cell repertoire could be loss of some peripheral tolerance if the T regulatory cells protecting a particular tissue are particularly skewed toward expressing TRBC1 or TRBC2. However, ultimately, the toxicities associated with depletion of TRBC1 + or TRBC2 + cells could only be examined in a clinical trial.
In summary, we have demonstrated a new approach to the investigation and targeting of T cell malignancies through distinguishing between two possible TCR β-chain constant regions. Using CAR T cells targeting one constant region, we have demonstrated proof of concept. Exploration of the distribution of constant region usage by unselected normal T cells and those providing specific viral immunity suggests that such an approach would not lead to clinically important immunosuppression. We hope that this approach heralds the application of potent targeted immunotherapeutics to provide much needed enhancement in the treatment of T cell malignancies. 
ONLINE METhODS
Cell lines. HEK-293T and K562 cell lines were cultured in Iscove's modified Dulbecco's medium (IMDM) (Lonza, Basel, Switzerland) supplemented with 10% FBS (HyClone, GE, Buckinghamshire, UK) and 2 mM GlutaMAX (Invitrogen, CA). Jurkat, Jurkat TCR-knockout (and engineered variants), HD-Mar2, HPB-ALL, T-ALL1, and CCRF-CEM cells (all of T-ALL origin) and H9, MJ and HH cells (all of Sézary syndrome origin) were cultured in complete RPMI (RPMI-1640, Lonza, Basel, Switzerland) supplemented with 10% FBS and 2 mM GlutaMAX). Cells were maintained in a humidified atmosphere containing 5% CO 2 at 37 °C.
All cell lines were routinely tested for mycoplasma and for cell-surface expression of target antigens. All cell lines were obtained from the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) or Public Heath England collections. Jurkat TCR-knockout cells were a kind gift from the laboratory of H. Stauss (University College London).
Cloning, expression and purification of TCR protein. The C5861 TCR expressing a TRBC2 domain 33 and the ILA1 TCR expressing a TRBC1 domain 34 , constructed using a disulfide-linked construct, were used to produce the soluble α-and β-chain domains (variable and constant) for each TCR. Sequences encoding the TCR α and β chains were inserted into separate pGMT7 expression plasmids under the control of a T7 promoter. Competent Rosetta DE3 Escherichia coli cells (Merck, Darmstadt, Germany) were used to produce the C5861 and ILA1 TCRs in the form of inclusion bodies using 0.5 M IPTG to induce expression. Soluble C5861 and ILA1 TCRs were refolded as previously described 33 , purified by anion exchange (Poros 50HQ, Life Technologies, Cheshire, UK) and subjected to size-exclusion chromatography (S200 GR, GE Healthcare, Buckinghamshire, UK).
Surface plasmon resonance analysis. Binding analysis was performed using a Biacore T200 (GE Healthcare, Buckinghamshire, UK) equipped with a CM5 sensor chip as previously reported 35 . Briefly, 500-1,000 response units (RUs) of JOVI-1 antibody was linked by amine coupling to the chip surface. For the C5861 TRBC2-TCR, ten serial dilutions were injected over the immobilized JOVI-1 antibody and equilibrium binding analysis was performed. Equilibrium binding constant (K D (E)) values were calculated assuming a 1:1 interaction by plotting specific equilibrium-binding responses against protein concentrations, followed by nonlinear least squares fitting using the Langmuir binding equation.
For the ILA1 TRBC1-TCR, single kinetic injections were performed. For kinetics analysis, K on and K off values were calculated assuming 1:1 Langmuir binding and the data were analyzed using a global fit algorithm (BIAevaluation 3.1).
Cell staining and flow cytometry. Flow cytometry was performed using a BD LSR Fortessa instrument (BD Biosciences, NJ). FACS sorting was performed using a BD FACSAria (BD Biosciences, NJ). Staining steps were performed at room temperature for 20 min with PBS washes between steps. For staining of intracellular antigens, cells were fixed and permeabilized with 100 µl of Cytofix/Cytoperm (BD Biosciences, NJ) for 5 min before staining, and wash steps were performed using Perm/Wash (BD Biosciences, NJ). The following antibodies were used (all anti-human unless otherwise specified; clone IDs are given in parentheses): CD2 (TS1/8), CD3 (UCHT1), CD4 (OKT4), CD5 (UCHT2), CD7 (CD7-6B7), CD8 (SK1), human and murine CD11b (M1/70), CD14 (M5E2), CD19 (HIB19), CD25 (BC96), CD45 (HI30), CD45RA (HI100), CD56 (HCD56), CD57 (HCD57), CCR7 (GO43H7) and αβ TCR (T10B9), all from BioLegend (San Diego, CA); CD34 (Qbend10, R&D Systems, Oxford, UK); TRBC1 (JOVI-1, Ansell, Bayport, MN); and fixable viability dye (eBioscience, Thermo Fisher, Waltham, MA). Anti-TRBC1 CAR expression was detected by staining for the RQR8 marker 22 with anti-CD34 or by staining directly for the CAR single-chain variable fragment (scFv) with goat anti-murine Fab. All antibodies other than JOVI-1 were validated by the manufacturer for diagnostic use. At least 5,000 target events were acquired per sample. Analyses were conducted using FlowJo v10 (Treestar, Ashland, OR).
Healthy donors and viral peptide stimulation assays. Approval for this study was obtained from the National Research Ethics Service, Research Ethics Committee 4 (REC, reference number 09/H0715/64). All healthy donors provided informed consent.
PBMCs from unselected healthy donors were isolated by Ficoll-Paque (GE Healthcare, Buckinghamshire, UK) gradient centrifugation and were resuspended at 2 × 10 6 cells/ml in 1 ml of complete medium in the wells of a 24-well plate. Overlapping peptide pools (15-mers with 11-residue overlaps) derived from commonly immunogenic viral proteins were obtained from JPT Technologies (Berlin, Germany). The viruses investigated (protein antigens in parentheses) were CMV (pp65) and AdV (hexon and penton). Peptide pools were supplied as dried pellets with 25 µg per peptide and were reconstituted in 50 µl of DMSO. To obtain a final concentration of 1 µg/ml for each peptide, 2 µl of each peptide pool was added to each well of PBMCs.
After an initial incubation for 1 h, brefeldin A (BD Biosciences, NJ) was added to prevent Golgi transport. After a further 14 h of culture, cells were washed and surface staining for CD4 and CD8 was performed. Cells were then fixed and permeablilized before staining with JOVI-1, anti-CD3 and anti-IFN-γ antibodies. Cells were next resuspended for FACS analysis. Viable cells were identified by exclusion of viability dye. Negative-control peptide pool (actin, a ubiquitous cytoskeletal protein) and a positive-control condition (PMA + ionomycin; Sigma-Aldrich, Darmstadt, Germany) were included. Low-frequency virus-specific T cells were identified by intracellular IFN-γ expression; the positive response threshold was set as >0.01% above negative-control staining. Invariant natural killer T cell isolation. PBMCs were isolated from blood bags obtained from healthy donors (Welsh Blood Service) using standard density gradient centrifugation. iNKT cells were purified from PBMCs by magnetic separation using anti-iNKT-TCR beads (Miltenyi Biotec) according to the manufacturer's recommendations. The purified cell fraction was subsequently expanded with phytohemagglutinin and allogeneic irradiated feeders from three donors. After a minimum of 14 d following expansion, cells were phenotyped and used in functional assays.
Identification of T cell differentiation
The Molt-3 cell line (endogenously expressing CD1d) was pulsed overnight with 100 ng/ml α-galactosylceramide (αGalCer; Sigma). iNKT lines were subsequently co-incubated with Molt-3 cells pulsed with αGalCer for 5 h in the presence of monensin, brefeldin A and anti-CD107a antibody (all from BD Biosciences) according to the manufacturer's recommendations. iNKT lines were also incubated with medium only and with Molt-3 cells pulsed with vehicle only (DMSO). iNKTs were identified by upregulation of CD107a and IFN-γ in response to Molt-3 cells pulsed with αGalCer.
Retroviral transduction of T cells. RD114-pseudotyped supernatant was generated as follows. HEK-293T cells were transfected with vector plasmid; RDF, an expression plasmid to supply RD114 envelope (a gift from M. Collins, University College London); and PeqPam-env, a Gag-Pol expression plasmid (a gift from E. Vanin, Baylor College of Medicine). Transfection was facilitated using GeneJuice (Merck, Darmstadt, Germany). PBMC transductions were performed as follows. T cells from normal donors were isolated by Ficoll (GE, Buckinghamshire, UK) gradient centrifugation and stimulated with phytohemagglutinin (Sigma-Aldrich, Darmstadt, Germany) at 5 mg/ml. IL-2 (GenScript, Nanjing, China; 100 IU/ml) was added following overnight stimulation. On day 3, T cells were collected, plated on retronectin (Takara, Nojihigashi, Japan) with retroviral supernatant, and centrifuged at 1,000g for 40 min. Transduction efficiency was determined on days 6-7 following initial collection, and further experiments were commenced on days 7-10 following initial collection. PBMCs were maintained in complete RPMI.
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Experimental design 1. Sample size
Describe how sample size was determined. Cohort sizes were based on number required to demonstrate 90% reduction in tumour bioluminescence, 95% confidence with 80% power.
Data exclusions
Describe any data exclusions.
No exclusions were pre-specified or included for the survival or specificity studies.
For the PBMC-engraftment study, animals were excluded (before randomisation) if they failed to engraft either tumour or PBMCs. See Supp Fig 4 
Replication
Describe whether the experimental findings were reliably reproduced.
One repeated animal experiment (Jurkat /PBMC engrafment study) failed due to death of all animals from GvHD. Other than this experiments were consistent, and all data represents either pooled data from multiple independent experiments or representative data from one experiment., as indicated.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Neither randomisation nor blinding was done during the in vivo study. However, mice were matched based on the tumor signal for control and treatment groups before infusion of control or gene-modified T-cells.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not performed as differences between control/ treated mice were so marked that this would have been futile, and manpower issues did not allow this.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
